OmniAb Unveils xPloration Partner Access Program for Enhanced Antibody Discovery and Development

OmniAb introduces the xPloration Partner Access Program, allowing current partners to purchase the platform for enhanced antibody discovery and development capabilities. The xPloration instrument leverages machine learning and AI, and provides advantages in speed, throughput, and ease of use. The program increases OmniAb's reach and adds new revenue streams, furthering its mission to push the frontiers of discovery technologies.

OmniAb, Inc. (NASDAQ: OABI) has announced the introduction of the xPloration Partner Access Program, a platform designed to enhance antibody discovery and development capabilities for its current partners. The program leverages machine learning and artificial intelligence to address challenges in primary B-cell screening, offering significant advantages in speed, throughput, and ease of use.

The xPloration instrument is a high-throughput single B-cell screening device that employs advanced algorithms to identify optimal antibodies and other target-binding proteins. This technology is particularly beneficial for pharmaceutical and biotech companies seeking to accelerate their drug development pipelines.

According to Matt Foehr, Chief Executive Officer of OmniAb, the xPloration Partner Access Program will create new business opportunities and contribute to both short- and long-term earnings and cash flow. The program aligns with OmniAb's mission to push the frontiers of discovery technologies and create value for its partners and stakeholders.

The introduction of the xPloration platform underscores OmniAb's commitment to innovation and its strategic initiatives to expand its reach and revenue streams. As of March 31, 2025, OmniAb had 95 active partners and 378 active programs, including 33 OmniAb-derived programs in clinical development or being commercialized.

The program was announced alongside OmniAb's first-quarter 2025 financial results, which showed a net loss of $18.2 million, or $0.17 per share, compared to a net loss of $19.0 million, or $0.19 per share, for the same period in 2024. Revenue for the first quarter of 2025 was $4.2 million, an increase of $0.4 million compared to the same period in 2024.

OmniAb's 2025 outlook remains on track, with guidance for revenue in the range of $20 million to $25 million and operating expense guidance of $85 million to $90 million. The company expects 2025 cash use to be lower than that of 2024, with cash use in 2024 being $38.9 million, excluding the 2024 ATM issuance.

OmniAb will showcase the xPloration instrument at the 21st Annual PEGS Boston Summit, taking place from May 12-16 at the Omni Boston Hotel at the Seaport. The company's management will host a conference call on May 9, 2025, at 4:30 p.m. Eastern time to discuss the announcement and answer questions. [1]

References:
[1] https://www.businesswire.com/news/home/20250508302653/en/OmniAb-Reports-First-Quarter-2025-Financial-Results-and-Business-Highlights